Molecular point-of-care (mPOC) is a multi-billion dollar market with expanding international intrigue. Though the mPOC market is led by North America and Europe, the Asia-Pacific region makes up 10% of the market’s worldwide sales, with…

The first NGS system was approved for clinical use by the FDA only in 2013. Hence, the market segment is quite new, even though a significant industry exists for LDTs performed as testing services on…